Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer

首页 > 成果 > 详情

认领

导出

Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Ye, Zhuo-miao;Xu, Zhe;Li, Huan;Li, Qian

通讯作者：

Li, Q.

作者机构：

[Ye, Zhuo-miao; Li, Huan] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China.

[Xu, Zhe] Cent South Univ, Xiangya Hosp, Dept Pharm, Changsha, Hunan, Peoples R China.

[Li, Qian] Univ South China, Affiliated Changsha Cent Hosp, Hengyang Med Sch, Dept Infect Dis, Hengyang, Hunan, Peoples R China.

通讯机构：

[Li, Q.] T

The Affiliated Changsha Central Hospital, Hunan, China

语种：

英文

关键词：

cost-effectiveness analysis;durvalumab;Biliary tract cancer;chemotherapy;Markov model

期刊：

Frontiers in Public Health

ISSN：

2296-2565

年：

2023

卷：

页码：

1046424

DOI：

10.3389/fpubh.2023.1046424

基金类别：

Project supported by the Natural Science Foundation of Changsha, China (No. kq2202043); Foundation of the Changsha Central Hospital (No. YNKY202236) to QL. National Natural Science Foundation of China (Grant No. 81900201) and Youth Foundation of Xiangya Hospital (No. 2017Q09) to HL.

机构署名：

本校为其他机构

摘要：

Objective: The TOPAZ-1 trial reported a significant survival benefit of durvalumab in combination with chemotherapy for the first-line treatment of biliary tract cancer (BTC). However, no studies have evaluated the economics of this treatment option. The aim of this study was to assess the cost effectiveness of durvalumab plus chemotherapy compared to placebo plus chemotherapy from the perspective of US and Chinese payers. Methods: Based on clinical data from the TOPAZ-1 trial, a Markov model was developed to simulate 10-year life expectancy an...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问